Journal
AIDS
Volume 36, Issue 10, Pages 1465-1468Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0000000000003246
Keywords
-
Categories
Funding
- Swiss National Science Foundation [31CA30_196245, P4P4PM_194496, 177499, 201369, P300PB_177933]
- Pandemiefonds of the University of Zurich Foundation to Alexandra Trkola
- Promedica Foundation [14851 M]
- Swiss National Science Foundation (SNF) [P4P4PM_194496, 31CA30_196245] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV were identified. The antibody response was higher in people with HIV under the age of 60, with a CD4(+) cell count greater than 350 cells/mu l, and vaccinated with Moderna's mRNA-1273 compared to Pfizer-BioNTech's BNT162b2. Prior infection with SARS-CoV-2 boosted the antibody response, while smokers had a lower overall antibody response. Elderly people with HIV and those with a low CD4(+) cell count should be prioritized for booster vaccinations.
We identified determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV (PWH). Antibody response was higher among PWH less than 60 years, with CD4(+) cell count superior to 350 cells/mu l and vaccinated with mRNA-1273 by Moderna compared with BNT162b2 by Pfizer-BioNTech. Preinfection with SARS-CoV-2 boosted the antibody response and smokers had an overall lower antibody response. Elderly PWH and those with low CD4(+) cell count should be prioritized for booster vaccinations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available